JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure

It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.

It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.

Scrip and its sister publication The Pink Sheet DAILY published interviews with big pharma CEOs at Eli Lilly & Co....

Welcome to Scrip

Create an account to read this article

More from Dermatological

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By 

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

More from Therapy Areas